Please click on any item below to read more. If you wish to reproduce any items from The Tennessean newspaper (Nashville, TN), please cite as follows: "Reprinted with permission from The Tennessean" and include the date of publication. No other changes are permitted.
FDA's OK Will Propel Lynch into Sales Push
TV Interview with BioMimetic Therapeutics CEO Dr. Samuel Lynch
BioMimetic: PMA in Progress
"It is an exciting and busy time for us"
Direct Hit: BioMimetic Achieves Enrollment Target
Synthetic 'Dust' May Replace Bone Grafts
BioMimetic Scoring Again
BioMimetic's PDGF-Based Bone Therapy Wins in Trial
Small Cap Summer Blockbusters
Technology Separates It From Field
BioMimetic Ends First Trading Day at $8.25
After First Product Approval, BioMimetic Seeks $50M IPO
Filing Seeks Area's First Biotech IPO
Discovery Emerges as Dental Product for Bone Restoration
BioMimetic's PDGF Product Approved In Dental Indication